The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound

Autor: Maria Gabriella Brasca, Claudia Covaciu, Marina Ciomei, Ester Alvino, Enzo Bonmassar, Daniele Castiglia, Lauretta Levati, Giuseppe Starace, Stefania D'Atri, Alberto Garbin, Simona Caporali

Publikováno v: Pharmacological research
61(5) (2010): 437–448.
info:cnr-pdr/source/autori:(a)Simona Caporali; (b)Ester Alvino; (b, c)Giuseppe Starace; (d)Marina Ciomei; (d)Maria Gabriella Brasca; (a)Lauretta Levati; (a)Alberto Garbin; (e)Daniele Castiglia; (e)Claudia Covaciu; (b,f)Enzo Bonmassar; (a)Stefania D'Atri/titolo:The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound/doi:/rivista:Pharmacological research (Print)/anno:2010/pagina_da:437/pagina_a:448/intervallo_pagine:437–448/volume:61(5)

PHA-848125 is a novel cyclin-dependent kinase inhibitor under Phase I/II clinical investigation. In this study, we describe, for the first time, the effect of PHA-848125 on human melanoma cells in vitro. Seven melanoma cell lines with different sensi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79df535e5f2be37ddd7a90b4c729ee5
https://pubmed.ncbi.nlm.nih.gov/20026273